SOCS1 is Significantly Up-regulated in Nutlin-3-treated P53wild-type B Chronic Lymphocytic Leukemia (B-CLL) Samples and Shows an Inverse Correlation with MiR-155

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2012 Jan 13

PMID 22238073

Citations 7

Authors

Maria Grazia di Iasio

Alessia Norcio

Elisabetta Melloni

Giorgio Zauli

Affiliations

Soon will be listed here.

Abstract

The basal SOCS1 mRNA levels were significantly lower in p53(mutated) BJAB and MAVER leukemic cell lines with respect to p53(wild-type) SKW6.4 and JVM-2 leukemic cell lines, p53(wild-type) primary B chronic lymphocytic leukemia (B-CLL) cells and primary normal peripheral blood mononuclear cells (PBMC). Moreover, the MDM2 small molecule inhibitor Nutlin-3 significantly increased the levels of SOCS1 mRNA in both primary p53(wild-type) B-CLL cells as well as in p53(wild-type) B leukemic cell lines, but not in p53(mutated) B leukemic cell lines nor in primary PBMC. Of note, a significant inverse correlation was observed between SOCS1 mRNA and miR-155 levels in Nutlin-3-treated primary B-CLL cells and PBMC, suggesting that the miRNA-155/SOCS1 axis represents a potentially important therapeutic target of Nutlin-3 in B-CLL.

Citing Articles

SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis.

Pandey R, Bakay M, Hakonarson H Front Immunol. 2023; 14:1271102.

PMID: 38022642 PMC: 10643230. DOI: 10.3389/fimmu.2023.1271102.

The Emerging Role of Suppressors of Cytokine Signaling (SOCS) in the Development and Progression of Leukemia.

Keewan E, Matlawska-Wasowska K Cancers (Basel). 2021; 13(16).

PMID: 34439155 PMC: 8393695. DOI: 10.3390/cancers13164000.

Loss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemia.

Zhou K, Zhang W, Zhang Q, Gui R, Zhao H, Chai X Oncotarget. 2017; 8(15):25469-25481.

PMID: 28424416 PMC: 5421944. DOI: 10.18632/oncotarget.16038.

MicroRNA-155 expression is independently predictive of outcome in chordoma.

Osaka E, Kelly A, Spentzos D, Choy E, Yang X, Shen J Oncotarget. 2015; 6(11):9125-39.

PMID: 25823817 PMC: 4496207. DOI: 10.18632/oncotarget.3273.

Role of microRNAs on therapy resistance in Non-Hodgkin's lymphoma.

Zheng R, Jiang Y, Wang X Int J Clin Exp Med. 2015; 7(11):3818-32.

PMID: 25550890 PMC: 4276148.

References

Gibellini D, Bassini A, Pierpaoli S, Bertolaso L, Milani D, Capitani S . Extracellular HIV-1 Tat protein induces the rapid Ser133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. J Immunol. 1998; 160(8):3891-8. View

Chim C, Wong K, Loong F, Srivastava G . SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway. Leukemia. 2003; 18(2):356-8. DOI: 10.1038/sj.leu.2403216. View

Frantsve J, Schwaller J, Sternberg D, Kutok J, Gilliland D . Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol. 2001; 21(10):3547-57. PMC: 100276. DOI: 10.1128/MCB.21.10.3547-3557.2001. View

Secchiero P, Melloni E, di Iasio M, Tiribelli M, Rimondi E, Corallini F . Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood. 2009; 113(18):4300-8. DOI: 10.1182/blood-2008-11-187708. View

di Iasio M, Addobbati R, Radillo O, Voltan R . Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples. Invest New Drugs. 2011; 30(4):1761-5. DOI: 10.1007/s10637-011-9695-4. View

Jongen-Lavrencic M, Sun S, Dijkstra M, Valk P, Lowenberg B . MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood. 2008; 111(10):5078-85. DOI: 10.1182/blood-2008-01-133355. View

Jiang S, Zhang H, Lu M, He X, Li Y, Gu H . MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010; 70(8):3119-27. DOI: 10.1158/0008-5472.CAN-09-4250. View

Wang M, Tan L, Dijkstra M, van Lom K, Robertus J, Harms G . miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. J Pathol. 2008; 215(1):13-20. DOI: 10.1002/path.2333. View

Androulidaki A, Iliopoulos D, Arranz A, Doxaki C, Schworer S, Zacharioudaki V . The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity. 2009; 31(2):220-31. PMC: 2865583. DOI: 10.1016/j.immuni.2009.06.024. View

10.

Marton S, Garcia M, Robello C, Persson H, Trajtenberg F, Pritsch O . Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia. 2007; 22(2):330-8. DOI: 10.1038/sj.leu.2405022. View

11.

Secchiero P, Barbarotto E, Tiribelli M, Zerbinati C, di Iasio M, Gonelli A . Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2006; 107(10):4122-9. DOI: 10.1182/blood-2005-11-4465. View

12.

Alexander W . Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol. 2002; 2(6):410-6. DOI: 10.1038/nri818. View

13.

Lu L, Thai T, Calado D, Chaudhry A, Kubo M, Tanaka K . Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity. 2009; 30(1):80-91. PMC: 2654249. DOI: 10.1016/j.immuni.2008.11.010. View

14.

Cammarata G, Augugliaro L, Salemi D, Agueli C, La Rosa M, Dagnino L . Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am J Hematol. 2010; 85(5):331-9. DOI: 10.1002/ajh.21667. View

15.

Secchiero P, Zerbinati C, di Iasio M, Melloni E, Tiribelli M, Grill V . Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab. 2007; 8(4):395-403. DOI: 10.2174/138920007780655432. View

16.

Saddler C, Ouillette P, Kujawski L, Shangary S, Talpaz M, Kaminski M . Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood. 2007; 111(3):1584-93. DOI: 10.1182/blood-2007-09-112698. View

17.

Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F . Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol. 2005; 166(2):557-63. PMC: 1602326. DOI: 10.1016/S0002-9440(10)62277-8. View

18.

Galm O, Yoshikawa H, Esteller M, Osieka R, Herman J . SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood. 2002; 101(7):2784-8. DOI: 10.1182/blood-2002-06-1735. View

19.

Secchiero P, di Iasio M, Gonelli A, Zauli G . The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr Pharm Des. 2008; 14(21):2100-10. DOI: 10.2174/138161208785294663. View

20.

Reddy J, Shivapurkar N, Takahashi T, Parikh G, Stastny V, Echebiri C . Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene. 2004; 24(4):732-6. DOI: 10.1038/sj.onc.1208032. View